Kilitch Drugs (India) Limited (KILITCH.BO)
INR 341.85
(-2.37%)
INR 341.85
(-2.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 146.01 Million INR | 39.75% |
| 2022 | 104.48 Million INR | 41.82% |
| 2021 | 73.67 Million INR | 100.68% |
| 2020 | 36.71 Million INR | 336.0% |
| 2019 | 8.42 Million INR | -78.01% |
| 2018 | 38.29 Million INR | -25.67% |
| 2017 | 51.52 Million INR | 157.96% |
| 2016 | -88.89 Million INR | 20.56% |
| 2015 | -111.9 Million INR | -3766.93% |
| 2014 | -2.89 Million INR | -124.6% |
| 2013 | 11.76 Million INR | -64.16% |
| 2012 | 32.82 Million INR | -95.7% |
| 2011 | 763.1 Million INR | 627.6% |
| 2010 | 104.88 Million INR | 2.51% |
| 2009 | 102.31 Million INR | -8.18% |
| 2008 | 111.43 Million INR | -1.56% |
| 2007 | 113.2 Million INR | 1026.2% |
| 2006 | 10.05 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 13.4 Million INR | -62.71% |
| 2023 Q4 | 35.94 Million INR | 23.54% |
| 2023 Q1 | 33.57 Million INR | -5.79% |
| 2023 Q2 | 47.41 Million INR | 41.22% |
| 2023 Q3 | 29.09 Million INR | -38.64% |
| 2023 FY | 146.01 Million INR | 39.75% |
| 2022 Q2 | 24.27 Million INR | 16.37% |
| 2022 Q4 | 35.63 Million INR | 50.31% |
| 2022 FY | 104.48 Million INR | 41.82% |
| 2022 Q1 | 20.86 Million INR | -28.01% |
| 2022 Q3 | 23.7 Million INR | -2.35% |
| 2021 Q3 | 11.24 Million INR | -47.84% |
| 2021 Q1 | 11.87 Million INR | 67.61% |
| 2021 FY | 73.67 Million INR | 100.68% |
| 2021 Q4 | 28.98 Million INR | 157.63% |
| 2021 Q2 | 21.56 Million INR | 81.57% |
| 2020 FY | 36.71 Million INR | 336.0% |
| 2020 Q4 | 7.08 Million INR | -68.0% |
| 2020 Q3 | 22.14 Million INR | 6.38% |
| 2020 Q2 | 20.81 Million INR | 256.08% |
| 2020 Q1 | -13.33 Million INR | -6.94% |
| 2019 FY | 8.42 Million INR | -78.01% |
| 2019 Q1 | -1.93 Million INR | -139.02% |
| 2019 Q2 | 13.37 Million INR | 791.32% |
| 2019 Q3 | 9.45 Million INR | -29.36% |
| 2019 Q4 | -12.47 Million INR | -231.98% |
| 2018 FY | 38.29 Million INR | -25.67% |
| 2018 Q4 | 4.95 Million INR | 110.3% |
| 2018 Q3 | -48.15 Million INR | -214.45% |
| 2018 Q2 | 42.07 Million INR | 6.74% |
| 2018 Q1 | 39.41 Million INR | 0.0% |
| 2017 FY | 51.52 Million INR | 157.96% |
| 2016 FY | -88.89 Million INR | 20.56% |
| 2015 FY | -111.9 Million INR | -3766.93% |
| 2014 FY | -2.89 Million INR | -124.6% |
| 2013 FY | 11.76 Million INR | -64.16% |
| 2012 Q4 | 5.12 Million INR | -19.21% |
| 2012 Q3 | 6.34 Million INR | 380.38% |
| 2012 Q2 | -2.26 Million INR | -107.87% |
| 2012 FY | 32.82 Million INR | -95.7% |
| 2012 Q1 | 28.75 Million INR | 0.0% |
| 2011 FY | 763.1 Million INR | 627.6% |
| 2010 FY | 104.88 Million INR | 2.51% |
| 2009 FY | 102.31 Million INR | -8.18% |
| 2008 FY | 111.43 Million INR | -1.56% |
| 2007 FY | 113.2 Million INR | 1026.2% |
| 2006 FY | 10.05 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 97.629% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.54% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 96.899% |
| Granules India Limited | 4.05 Billion INR | 96.397% |
| Indoco Remedies Limited | 984.6 Million INR | 85.17% |
| Achyut Healthcare Limited | 5.73 Million INR | -2447.348% |
| Ajanta Pharma Limited | 8.16 Billion INR | 98.211% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.187% |
| Alpa Laboratories Limited | 167.76 Million INR | 12.965% |
| Brooks Laboratories Limited | -195.91 Million INR | 174.528% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 90.959% |
| Bajaj HealthCare Limited | -837.93 Million INR | 117.426% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 80.649% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.738% |
| Eris Lifesciences Limited | 3.91 Billion INR | 96.275% |
| FDC Limited | 3.05 Billion INR | 95.216% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.972% |
| Gufic Biosciences Limited | 861.35 Million INR | 83.048% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 96.531% |
| Ipca Laboratories Limited | 5.47 Billion INR | 97.332% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 34.998% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 174.012% |
| Lasa Supergenerics Limited | -217.3 Million INR | 167.193% |
| Laurus Labs Limited | 1.6 Billion INR | 90.905% |
| Lupin Limited | 19.14 Billion INR | 99.237% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.237% |
| Medicamen Biotech Limited | 109.31 Million INR | -33.578% |
| Medico Remedies Limited | 82.9 Million INR | -76.114% |
| Megasoft Limited | -127.46 Million INR | 214.551% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.948% |
| Piramal Pharma Limited | 178.2 Million INR | 18.062% |
| RPG Life Sciences Limited | 876.6 Million INR | 83.343% |
| Sigachi Industries Limited | 571.8 Million INR | 74.464% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.848% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 95.137% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 42.319% |
| Unichem Laboratories Limited | -704.74 Million INR | 120.719% |
| Wanbury Limited | 559.56 Million INR | 73.906% |
| Windlas Biotech Limited | 581.87 Million INR | 74.906% |
| ZIM Laboratories Limited | 172.46 Million INR | 15.337% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.622% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 103.771% |
| Divi's Laboratories Limited | 16 Billion INR | 99.087% |
| Hester Biosciences Limited | 188.89 Million INR | 22.699% |
| Procter & Gamble Health Limited | 2 Billion INR | 92.735% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 67.533% |
| Bal Pharma Limited | 73.92 Million INR | -97.524% |
| Strides Pharma Science Limited | -706.14 Million INR | 120.678% |
| Venus Remedies Limited | 284.9 Million INR | 48.75% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 93.268% |
| Nectar Lifesciences Limited | 49.95 Million INR | -192.32% |
| Shilpa Medicare Limited | 318.74 Million INR | 54.191% |
| Aarti Drugs Limited | 1.71 Billion INR | 91.482% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 89.138% |
| Suven Life Sciences Limited | -1.05 Billion INR | 113.896% |
| Ind-Swift Limited | 142.31 Million INR | -2.601% |
| Valiant Laboratories Limited | 3.19 Million INR | -4468.648% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 97.358% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 102.573% |
| Themis Medicare Limited | 435.23 Million INR | 66.452% |
| Hikal Limited | 696.02 Million INR | 79.022% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.118% |
| Sequent Scientific Limited | -358.69 Million INR | 140.708% |
| Novartis India Limited | 851.9 Million INR | 82.86% |
| Wockhardt Limited | -4.63 Billion INR | 103.154% |
| Jubilant Pharmova Limited | 771 Million INR | 81.062% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -1958.855% |
| Neuland Laboratories Limited | 3 Billion INR | 95.134% |
| Morepen Laboratories Limited | 961.59 Million INR | 84.816% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 260.955% |